Changes

{{#seo:

{{#seo:

|title=Obesity and Metabolic Syndrome  

|title=Obesity and Metabolic Syndrome  

|type=article

|type=article

}}

}}

{{Infobox

{{Infobox

|title =  Contributors

|title =  Contributors

|label3 = Reviewer  

|label3 = Reviewer  

|data3 = Basisht G.²

|data3 = [[Gopal Basisht|Basisht G.]]²

|label4 = Editors

|label4 = Editors

|data4 = Deole Y.S.², Aneesh E.G.², Basisht G. ²  

|data4 = [[Yogesh Deole|Deole Y.S.]]², Aneesh E.G.², [[Gopal Basisht|Basisht G.]]²  

|label5 = Affiliations

|label5 = Affiliations

|label6 = Correspondence email:

|label6 = Correspondence email:

|data6 = carakasamhita@gmail.com

|data6 = jeevanrekha1996@rediffmail.com, carakasamhita@gmail.com

|label7 = Date of first publication:

|label7 = Publisher

|data7 = June 09, 2021

|data7 = [[Charak Samhita Research, Training and Development Centre]], I.T.R.A., Jamnagar, India

|label8 = DOI

|label8 = Date of first publication:

|data8 = Under process

 

|label9 = DOI

|data9 = 10.47468/CSNE.2021.e01.s09.060

}}  

}}  

'''Principles of Diagnosis and Management of Metabolic syndrome and Obesity in Ayurveda'''

'''Principles of Diagnosis and Management of Metabolic syndrome and Obesity in Ayurveda'''

 

<p style="text-align:justify;">This article is based on lecture delivered by Dr. Mukund Sabnis in Prof.M.S.Baghel Memorial Lecture Series on May 09, 2021.The video lecture can be accessed on the link of [https://fb.watch/8l93wbtQXx/ facebook page.]

This article is based on lecture delivered by Dr. Mukund Sabnis in Prof.M.S.Baghel Memorial Lecture Series on May 09, 2021.

<br/>

 

<div style='text-align:justify;'>

Metabolic syndrome is a group of several cardiovascular risk factors like insulin resistance, obesity, atherogenic dyslipidemia and hypertension. These conditions are interrelated and share underlying mediators, mechanisms and pathways. There has been recent controversy about its definition and its utility. Metabolic syndrome is not an ultimate diagnosis.  Metabolic syndrome is a subgroup of patients with shared pathophysiology who are at high risk of developing cardiovascular disease and type 2 diabetes. Pathophysiology and disease pathogenesis can be better understood by observing the clinical features of metabolic syndrome and their interrelation.

Metabolic syndrome is a group of several cardiovascular risk factors like insulin resistance, obesity, atherogenic dyslipidemia and hypertension. These conditions are interrelated and share underlying mediators, mechanisms and pathways. There has been recent controversy about its definition and its utility. Metabolic syndrome is not an ultimate diagnosis.  Metabolic syndrome is a subgroup of patients with shared pathophysiology who are at high risk of developing cardiovascular disease and type 2 diabetes. Pathophysiology and disease pathogenesis can be better understood by observing the clinical features of metabolic syndrome and their interrelation.

 

[[Ayurveda]] has a vast scope in the management of metabolic syndrome. Clubbing of modern medicine concepts with Ayurveda is essential for this. The pathophysiology of metabolic syndrome shall be clubbed with disorders due to overnutrition (santarpanajanya vyadhi) in [[Ayurveda]].  [Cha.Sa. [[Sutra Sthana]] 23/3-5]

[[Ayurveda]] has a vast scope in the management of metabolic syndrome. Clubbing of modern medicine concepts with Ayurveda is essential for this. The pathophysiology of metabolic syndrome shall be clubbed with disorders due to overnutrition (santarpanajanya vyadhi) in [[Ayurveda]].  [Cha.Sa. [[Sutra Sthana]] 23/3-5] </p>

==Definition==

==Definition==

In fatty liver, in the first stage, insulin resistance is observed at the hepatocytes. There is a reduction in fatty oxidation; increase in fatty acid influx into liver; increased lipogenesis and increased triglycerides. The second stage is lipid peroxidation. So the management should target lipid peroxidation, TNF-alpha, cytokine cascade, reducing the liquid/slimy content (kleda), correcting the metabolism ([[agni]]) etc.

In fatty liver, in the first stage, insulin resistance is observed at the hepatocytes. There is a reduction in fatty oxidation; increase in fatty acid influx into liver; increased lipogenesis and increased triglycerides. The second stage is lipid peroxidation. So the management should target lipid peroxidation, TNF-alpha, cytokine cascade, reducing the liquid/slimy content (kleda), correcting the metabolism ([[agni]]) etc.

Ayurvedic interventions considerably control the hormones - adiponectin and leptin secreted by adipose tissue. The treatment creates insulin sensitivity and reduces inflammation at adipocyte level. Adiponectin is inversely proportional to obesity. If weight is more, adiponectin level is less and vice versa. However, in people having optimum [[meda]] (meda sara), adiponectin level increases with weight.  

Ayurvedic interventions considerably control the hormones - adiponectin and leptin secreted by adipose tissue. The treatment creates insulin sensitivity and reduces inflammation at adipocyte level. Adiponectin is inversely proportional to obesity. If weight is more, adiponectin level is less and vice versa. However, in people having optimum [[meda dhatu]] (meda sara), adiponectin level increases with weight.

=== Effect of therapeutic enema ( [[basti]]) as a treatment in obesity===

=== Effect of therapeutic enema ( [[basti]]) as a treatment in obesity===

[[Ashtauninditiya Adhyaya]], [[Santarpaniya Adhyaya]], [[Prameha Nidana Adhyaya]], [[Prameha Chikitsa Adhyaya]]

[[Ashtauninditiya Adhyaya]], [[Santarpaniya Adhyaya]], [[Prameha Nidana Adhyaya]], [[Prameha Chikitsa Adhyaya]]

== Reference Source==  

== Reference Source==